Literature DB >> 27746992

Percutaneous left atrial appendage closure: here to stay.

Lim Eng1, Jacqueline Saw1.   

Abstract

Year:  2016        PMID： 27746992      PMCID： PMC5059271          DOI： 10.21037/jtd.2016.08.99

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  17 in total

1.  Left atrial appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey.

Authors:  Laurent Pison; Tatjana S Potpara; Jian Chen; Torben B Larsen; Maria Grazia Bongiorni; Carina Blomström-Lundqvist
Journal:  Europace       Date:  2015-04       Impact factor: 5.214

2.  Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry.

Authors:  Vivek Y Reddy; David Holmes; Shephal K Doshi; Petr Neuzil; Saibal Kar
Journal:  Circulation       Date:  2011-01-17       Impact factor: 29.690

3.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

4.  Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology).

Authors:  Vivek Y Reddy; Sven Möbius-Winkler; Marc A Miller; Petr Neuzil; Gerhard Schuler; Jens Wiebe; Peter Sick; Horst Sievert
Journal:  J Am Coll Cardiol       Date:  2013-04-10       Impact factor: 24.094

5.  Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.

Authors:  David R Holmes; Saibal Kar; Matthew J Price; Brian Whisenant; Horst Sievert; Shephal K Doshi; Kenneth Huber; Vivek Y Reddy
Journal:  J Am Coll Cardiol       Date:  2014-07-08       Impact factor: 24.094

6.  Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke.

Authors:  Eva-Lotta Glader; Maria Sjölander; Marie Eriksson; Michael Lundberg
Journal:  Stroke       Date:  2010-01-14       Impact factor: 7.914

7.  Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study.

Authors:  Peter C Block; Steven Burstein; Paul N Casale; Paul H Kramer; Paul Teirstein; David O Williams; Mark Reisman
Journal:  JACC Cardiovasc Interv       Date:  2009-07       Impact factor: 11.195

8.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

9.  Percutaneous Left Atrial Appendage Closure With the Watchman Device: Long-Term Results Up to 5 Years.

Authors:  Jens Wiebe; Jennifer Franke; Katharina Lehn; Ilona Hofmann; Laura Vaskelyte; Stefan Bertog; Horst Sievert
Journal:  JACC Cardiovasc Interv       Date:  2015-12-28       Impact factor: 11.195

10.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.

Authors:  David R Holmes; Vivek Y Reddy; Zoltan G Turi; Shephal K Doshi; Horst Sievert; Maurice Buchbinder; Christopher M Mullin; Peter Sick
Journal:  Lancet       Date:  2009-08-15       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.